PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trial
Written by Ι Stock Market Media — October 28, 2019
PharmaCyte Biotech (OTCQB: PMCB) has a technology that could very well change the way a host of hard-to-treat diseases are treated for the foreseeable future. The company is closer than ever to its upcoming Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) that could give patients a new lease on life by shrinking their tumors enough so that the tumors can be removed surgically. It is an outcome that would ...
Read More →
28
OCT
Share
PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA
Written by Ι Stock Market Media — February 4, 2019
Clinical stage biotechnology company PharmaCyte Biotech (OTCQB: PMCB) is now closer than ever to reaching what would be a monumental milestone in the company’s history. Years of patience from PharmaCyte’s shareholders has now likely been whittled down to what should now be just months, and with the condensed timeline, the company is this close to what will be a landmark event—an “open” or approved Investigational New Drug application (IND) with the U.S. ...
Read More →
4
FEB
Share
PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology
Written by Ι Stock Market Media — June 6, 2018
PharmaCyte Biotech, Inc. (OTCQB: PMCB) is closing in on what will be a landmark event in this small company’s history—a clinical trial in the United States under the watchful eye of the most powerful drug regulatory agency in the world, the U.S. Food and Drug Administration (FDA). It would be the company’s first clinical trial ever and could serve as the event that changes the way solid cancerous tumors are treated, ...
Read More →
6
JUN
Share
Plandaí Biotechnology’s Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes
Written by Ι Stock Market Media — May 18, 2017
Plandaí Biotechnology (OTCQB: PLPL) announced that it will conduct a human clinical trial to study the effectiveness of using its highly bioavailable green tea extract, Phytofare® Catechin Complex, to regulate blood glucose levels in type 2 diabetics. If the positive data that was recently published in the Journal of Human Nutrition and Dietetics is any indicator, Plandaí should expect to receive its own positive data. The two studies could complement one another, and Plandaí’s ...
Read More →
18
MAY
Share
Plandai Biotechnology Gains Credibility with NutriBullet Deal
Written by Ι Stock Market Media — April 26, 2017
Plandaí Biotechnology (OTCQB: PLPL) expects Capital Brands, LLC, the developer, marketer, and distributor of both the wildly popular NutriBullet and NutriBullet SuperFoods, to launch its reformulated product, SuperFood Fat Burning Boost®, next month. SuperFood Fat Burning Boost® is being reformulated to include Plandaí’s Phytofare® Catechin Complex. This is a landmark moment for a company like Plandaí Biotechnology that has just recently moved from solely a research and development company to focusing more on sales and ...
Read More →
26
APR
Share
As Diabetes Becomes Global Epidemic, PharmaCyte Biotech’s Insulin Producing Cells Receive 20 Years of Protection
Written by Ι Stock Market Media — July 19, 2016
Worldwide the number of people living with diabetes has reached 422 million, and if the current trend continues, over 700 million people are expected to be living with diabetes by 2025. Diabetes has clearly become a healthcare crisis on a global scale, and PharmaCyte Biotech (OTCQB: PMCB) recently received some good news in the form of patent protection that will help the company do its part in bringing a treatment to tens of ...
Read More →
19
JUL
Share
